Recent progress in research and development of nucleoside analogues as anticancer agents

Chinese Journal of New Drugs

Volumn 21, Issue 21, 2012, Pages 2493-2498

  Liu, Yang ^a   Li, Ming Hua ^a   Xing, Xiang Hong ^a  

^a CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd   (China)

Author keywords

Anticancer agent; Nucleoside; Research progress

Indexed keywords

ANTINEOPLASTIC AGENT; NUCLEOSIDE ANALOG;

ARTICLE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE;

EID: 84879218472     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. MADER M M, HENRY J R. Antimetabolites[M]. JOHN B T, D J TRIGGLE. Comprehensive Medicinal Chemistry(II), Amsterdam: Elsevier Ltd, 2007: Volume 7, 55-79.
2. DEANGELO D J. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma[J]. Hematol Oncol Clin North Am, 2009, 23(5): 1121-1135.
3. BALAKRISHNAN K, NIMMANAPALLI R, RAVANDI F, et al. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells[J]. Blood, 2006, 108(7): 2392-2398.
4. BERMUDEZ A, PEREZ-VAZQUEZ G, INSUNZA A, et al. Flagida-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment[J]. Am J Hematol, 2012, 87(1): 42-44.
5. ANDERSON V R, PERRY C M. Fludarabine: a review of its use in non-Hodgkin's lymphoma[J]. Drugs, 2007, 67(11): 1633-1655.
6. GAVIN G, GIANCARLO C, STUART C, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis[J]. N Engl J Med, 2010, 362(5): 416-426.
7. ZHENCHUK A, LOTFI K, JULIUSSON G, et al. Mechanisms of anti-cancer action and pharmacology of clofarabine[J]. Biochem Pharmacol, 2009, 78(11): 1351-1359.
8. Van Den Neste E, Van Den Berghe G, Bontemps F. AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies[J]. Expert Opin Investig Drugs, 2010, 19(4): 571-578.
9. ZHANG W, WANG J, WANG H, et al. Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway[J]. Arterioscler Thromb Vasc Biol, 2010, 30(5): 1000-1006.
10. MUELLER C, HECKL-OESTREICHER B, LUTZ C. Clofarabine dietherphospholipid derivatives: US, 2010249055[P]. 2010-09-30.
11. DANIEL B L, PATRICK G J. 5-Fluorouracil Molecular Mechanisms of Cell Death[M]. RAKESH S. Apoptosis, Cell Signaling, and Human Diseases: Molecular Mechanisms(Volume 1), Totowa: Humana Press Inc, 2007: II, 263-278.
12. PORTSMOUTHD, HLAVATY J, RENNER M. Suicide genes forcancer therapy[J]. Mol Aspects Med, 2007, 28(1): 4-41.
13. BANG Y J. Capecitabine in gastric cancer[J]. Exp Rev Anticancer Ther, 2011, 11(12): 1791-1806.
14. GILBERTO D L L, JENNIFER S D, WILLIAM P P, et al. Final results of a prematurely discontinued phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2011, 68(4): 1067-1073.
15. FARHAD R. Primary refractory acute myeloid leukaemia-in search of better definitions and therapies[J]. Br J Haematol, 2011, 155(4): 413-419.
16. ADEMA A D, LAAN A C, MYHREN F, et al. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel[J]. Int J Oncol, 2010, 36(1): 285-294.
17. HECKER S J, ERION M D. Prodrugs of phosphates and phosphonates[J]. J Med Chem, 2008, 51(8): 2328-2345.
18. BOYER S H, SUN Z L, JIANG H J, et al. Synthesis and characterization of a novel-D-arabinofuranoside monophosphate for b liver-targeted prodrug of cytosine-1-the treatment of hepatocellular carcinoma[J]. J Med Chem, 2006, 49(26): 7711-7720.
19. WILLIAM B P, SUE C S, KAREN S G, et al. Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine[J]. Cancer Chemother Pharmacol, 2009, 64(2): 253-261.
20. SEROVA M, GALMARINI C M, GHOUL A. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells[J]. Br J Cancer, 2007, 97(5): 628-636.
21. ZENG W W, HUANG M, LI S. Advances in researches on the influence of gene polymorphisms on efficacy of gemcitabine[J]. Guoji Yaoxue Yanjiu Zazhi, 2011, 38(5): 345-348.
22. SYMONDS R P, DAVIDSON S E, CHAN S, et al. Scotcerv: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer[J]. Gynecol Oncol, 2011, 123(1): 105-109.
23. BENDER D M, BAO J, DANTZIG A H, et al. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine[J]. J Med Chem, 2009, 52(22): 6958-6961.
24. LI P K, GENG X P, ZHU L X. DNA methylation inhibitors: research advances[J]. Guoji Yaoxue Yanjiu Zazhi, 2010, 37(3): 198-202.
25. ZHAO Y SH, CHANG CH K. Research progress of DNA methylation and myelodysplastic syndrome[J]. Shanghai Jiaotong Daxue Xuebao(Yixueban), 2010, 30(12): 1557-1564.
26. CHUANG J C, WARNER S L, VOLLMER D, et al. S110, a 5-aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth[J]. Mol Cancer Ther, 2010, 9(5): 1443-1450.
27. LISA A H-T, MELANIE B T, MICHIKO I, et al. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine(TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies[J]. Invest New Drugs, 2012, 30(1): 316-326.
28. DIETERLE A, ORTH R, DAUBRAWA M, et al. The akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis[J]. Int J Cancer, 2009, 125(4): 932-941.
29. 2006, 17(7): 573-575.